Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

6
Rapid7 Integrates with Microsoft Azure to Provide Visibility, Analytics, and Automation for Cloud Security

2018-07-17 globenewswire
BOSTON, July 17, 2018 (GLOBE NEWSWIRE) -- Rapid7, Inc. (NASDAQ:RPD), powering SecOps through its visibility, analytics and automation cloud, today announced integration between Rapid7’s Insight platform and Microsoft Azure. This integration provides modern vulnerability management, analytics-driven incident detection for hybrid environments, and simplified agent deployment within the Azure infrastructure.
CLDS UCBB RPD MSFT

2
Atos launches a new Cloud Access Security Broker solution to enforce enterprises' security policies across hybrid Cloud environments

2018-06-28 globenewswire
Paris, June 28, 2018 - Atos, a global leader in digital transformation, launches a new Cloud Access Security Broker (CASB) Service using McAfee Skyhigh Security Cloud(TM) to safeguard enterprise applications and data in the Cloud.
CLDS UCBB ATONV

6
CLDS / Cloud Security Corporation EXTENSION

2018-05-30 sec.gov
SEC FILE NUMBER 000-54440
CLDS

7
CLDS / Cloud Security Corporation FORM 8-K (Current Report)

2018-05-27 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
CLDS

35
MobileIron (MOBL) to Report Q1 Earnings: What's in Store?

2018-04-23 zacks
MobileIron Inc. (MOBL - Free Report) is scheduled to report first-quarter 2018 results on Apr 26. Notably, the company has a mixed earnings surprise history. In the trailing four quarters, the stock has surpassed the Zacks Consensus Estimate twice while matching the same on two occasions. It has an average positive earnings surprise of 33.3%.
CLDS NINE KMI.WS WDC CTXS VZA MOBL KMI.PRA KMI GM.WS.A GM.WS.B GM.WS.C VZ GM KMR GM.WSB CVB KMRFZ

63
Akamai (AKAM) Strengthens Cloud Security Solutions Portfolio

2018-04-17 zacks
Akamai Technologies, Inc. (AKAM - Free Report) recently unveiled new enhancements to improve its cloud security solutions to ensure smooth digital operations.
CLDS APO.PRB APO.PRA WDC MS.PRE MS.PRF MS.PRG MS.PRA APO MS.PRI MS.PRK MS AKAM

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 18911V200